Related Experiment Video
Updated: Mar 14, 2026
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b
Brian A Neff1, Stephen G Voss1, Matthew L Carlson1
1Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota, U.S.A.
Objective/Hypothesis:
Eosinophilic otitis media (EOM) is a variant of chronic otitis media that is characterized by the development of thick mucoid middle ear effusion, adult onset bronchial asthma, sinonasal polyposis, and aspirin sensitivity. EOM is typically refractory to corticosteroid therapy and surgical intervention. Pegylated interferon (PEG-IFN) has effectively treated hypereosinophilic syndrome in clinical trials; however, the efficacy of this medication for EOM treatment remains undefined.
Study Design:
Retrospective, case series, tertiary academic center.
Methods:
A retrospective chart review was performed on EOM patients from 2008-2014. A total of 32 patients met the clinical criteria for EOM according to established diagnostic guidelines. Outcomes of all patients with severe, refractory EOM who initiated PEG-IFN therapy are reported.
Results:
Eight patients were treated with pegylated interferon-α 2a or 2b for refractory EOM. Half of the patients had significant side effects with interferon treatment. Three of these were able to continue at a reduced dosage without side effect reoccurrence, and one patient stopped the medication permanently. Four of eight (50%) patients had a complete clinical response with total resolution of otorrhea and normalization of middle ear mucosa, and were able to discontinue corticosteroid treatment. Two patients attempted to stop PEG-IFN therapy after prolonged symptom remission and had recurrent otorrhea. Both patients had symptom resolution after PEG-IFN reinitiation.
Conclusions:
These data demonstrate that pegylated interferon-α 2a and 2b therapy may benefit patients with severe, refractory EOM. Further larger studies with long-term follow-up are required to validate these early but promising results.
Level Of Evidence:
4. Laryngoscope, 127:1208-1216, 2017.
Insights
Pegylated interferon (PEG-IFN) shows promise in treating severe eosinophilic otitis media (EOM). Fifty percent of patients experienced complete symptom resolution, allowing for corticosteroid discontinuation.
Area of Science:
- Otolaryngology
- Immunology
- Pharmacology
Background:
- Eosinophilic otitis media (EOM) is a chronic condition with thick middle ear effusion, often associated with asthma, nasal polyps, and aspirin sensitivity.
- EOM frequently resists standard corticosteroid and surgical treatments.
Purpose of the Study:
- To evaluate the efficacy of pegylated interferon (PEG-IFN) in treating severe, refractory EOM.
- To assess PEG-IFN's safety and effectiveness in patients unresponsive to conventional therapies.
Main Methods:
- A retrospective case series design was employed, reviewing charts of EOM patients from 2008-2014.
- Eight patients with severe, refractory EOM were treated with pegylated interferon-α 2a or 2b.
- Outcomes including clinical response, side effects, and need for continued treatment were recorded.
Main Results:
- 50% of patients (4/8) achieved a complete clinical response, with resolution of otorrhea and normalization of middle ear mucosa.
- Treated patients were able to discontinue corticosteroid therapy.
- Half of the patients experienced side effects, with some managed by dose reduction.
Conclusions:
- Pegylated interferon-α (2a/2b) may offer a beneficial treatment option for severe, refractory EOM.
- Further large-scale studies are needed to confirm these preliminary findings and assess long-term outcomes.
More Related Videos
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
09:07Author Spotlight: Advancing Endoscopic Ossiculoplasty – Techniques, Innovations, and Practical Guidance for Clinical Integration
Published on: January 26, 2024
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:26Tonsillitis II: Management
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management